Long-Term Follow-Up for Adults Previously Treated with Zamtocabtagene Autoleucel Monitoring Safety and Outcomes in Lymphoma Patients

What this Trial Is About

This research follows adults who previously received the gene therapy treatment called zamtocabtagene autoleucel MB-CART2019.1. It is an observational long-term follow-up study focusing on people with forms of lymphoma, including Non Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma. The goal is to monitor participants for up to 15 years to understand any long-term effects related to the gene therapy. Participants do not receive any new treatment as part of this study. Instead, they will be observed regularly to check for gene therapy-related side effects, including delayed adverse events, and to assess the persistence of the CAR-T cells. Testing will include monitoring for replication competent lentivirus and evaluating long-term outcomes related to the therapy. During the study, participants will have yearly assessments to detect any new or worsening health issues related to the therapy, such as malignancies, neurological or autoimmune disorders, and hematologic conditions. Researchers will also measure survival rates, immune system recovery, and therapy effectiveness over time. The entire participation period can last up to 15 years, providing a comprehensive view of long-term safety and outcomes.

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU